Genetic Basis of Mitral Valve Prolapse (MVP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01719211
Recruitment Status : Recruiting
First Posted : November 1, 2012
Last Update Posted : March 22, 2018
Leducq Foundation
Information provided by (Responsible Party):
Robert A. Levine, MD, Massachusetts General Hospital

Brief Summary:
The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions. This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP. It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP. This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.

Condition or disease
Mitral Valve Prolapse

Detailed Description:
This is a genome-wide association study.

Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Genetic Basis of Mitral Valve Prolapse
Study Start Date : January 1999
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Discovery of the genetic basis of Mitral Valve Prolapse [ Time Frame: 5 years ]
    Genome-wide association

Biospecimen Retention:   Samples With DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients referred for 2D echo for MVP

Inclusion Criteria:

  • Mitral valve prolapse

Exclusion Criteria:

  • Other mitral valve diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01719211

Contact: Susan Slaugenhaupt, PhD 6176433217
Contact: Robert a levine, MD 6177241995

United States, Massachusetts
Mass General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Leducq Foundation
Principal Investigator: robert a levine, MD Mass General Hospital

Responsible Party: Robert A. Levine, MD, Cardiologist, Massachusetts General Hospital Identifier: NCT01719211     History of Changes
Other Study ID Numbers: 1999-p-007948
First Posted: November 1, 2012    Key Record Dates
Last Update Posted: March 22, 2018
Last Verified: March 2018

Keywords provided by Robert A. Levine, MD, Massachusetts General Hospital:
MVP, mitral valve

Additional relevant MeSH terms:
Mitral Valve Prolapse
Pathological Conditions, Anatomical
Heart Valve Prolapse
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases